Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

FranceBack to France

Clinical trials in Compiegne – page 2

29 clinical trials in Compiegne, France. Every trial is listed in the EU Clinical Trials Register and updated daily.

FranceOur site in FranceEssaisCliniques.fr(opens in a new tab)
Compiegne at a glance
29
clinical trials
  • Paediatric trials0
  • Research sites0
Type of trial
Recruitment status
Quick filters

29 trials in Compiegne

Open in trial search

Renal cell carcinoma

Recruiting

Study on Cabozantinib and Drug Combination for Untreated Metastatic Renal Cell Carcinoma in Intermediate and Poor Risk Patients

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Axitinib
  • Sponsor:Institut Gustave Roussy

Atypical mycobacterial infection

Recruiting

Study on Amikacin for Treating Mycobacterium Xenopi Lung Infection in Patients Using Amikacin and Drug Combination

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Amikacin
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Colon cancer

Recruiting

Study on the Effectiveness of Chemotherapy with Folinic Acid, Fluorouracil, and Irinotecan for Patients with Stage III Colon Cancer After Surgery

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Small intestine adenocarcinoma

Recruiting

Study on the Effectiveness of FOLFIRINOX and FOLFOX for Patients with Advanced Small Bowel Cancer Using Calcium Levofolinate, Irinotecan, and Oxaliplatin

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Levofolinate
  • Sponsor:Centre Hospitalier Universitaire De Dijon

Neoplasm

Recruiting

Study of Pemigatinib for Patients with Recurrent or Metastatic Solid Tumors with FGFR Gene Alteration

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pemigatinib
  • Sponsor:Unicancer

HER2 positive breast cancer

Recruiting

Study on Reducing Treatment for Patients with HER2-Positive Metastatic Breast Cancer Using Trastuzumab and Drug Combination After 2 Years of Controlled Disease

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Unicancer

Study on Luspatercept and Epoetin Alfa for Patients with Low-Risk Myelodysplastic Syndrome Without Ring Sideroblasts Who Did Not Respond to ESA

Recruiting
Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Epoetin Alfa
  • Sponsor:Groupe Francophone Des Myelodysplasies

Septic shock

Recruiting

Study on Landiolol Hydrochloride and Sodium Chloride for Reducing Mortality in Patients with Septic Shock and High Heart Rate

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire Amiens Picardie

Colorectal cancer metastatic

Not yet recruiting

Second‑line ivonescimab plus chemotherapy drug combination versus bevacizumab in patients with metastatic colorectal cancer without liver metastases

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Unicancer

Colorectal cancer

Not yet recruiting

Study of 5-Fluorouracil, Panitumumab, and Sotorasib for Patients with Advanced KRAS G12C Mutated Colorectal Cancer Not Eligible for Standard Chemotherapy

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Fluorouracil
  • Sponsor:Fondation Franc.Cancerologie Digestive

Arteriosclerosis

Not recruiting

A study to evaluate the effect of olpasiran on major cardiovascular events in patients with atherosclerotic cardiovascular disease and high levels of lipoprotein(a)

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Sponsor:Amgen Inc.

Arteriosclerosis

Not recruiting

Study on the Effects of Pelacarsen on Heart Disease in Patients with Cardiovascular Conditions

Investigational
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Pelacarsen
  • Sponsor:Novartis Pharma AG

Other cities in France

The busiest research cities in the country

All 382 cities in France

Clinical research in Compiegne

What the registry says about research in the country

01 Oncology Research

Groundbreaking trials focusing on colorectal cancer, breast cancer, and renal cell carcinoma treatments. Studies evaluate innovative therapeutic approaches including targeted therapies and immunotherapy combinations.

  • Advanced Colorectal Treatments
  • Triple-Negative Breast Cancer
  • Metastatic Cancer Management

Particular emphasis on personalized treatment approaches and circulating tumor DNA analysis for treatment decisions.

02 Cardiovascular Studies

Innovative research targeting atherosclerotic cardiovascular disease and related conditions. Trials evaluate new therapeutic agents for reducing cardiovascular events and managing risk factors.

  • Lipoprotein Management
  • Primary Prevention Strategies
  • Advanced Cardiovascular Therapeutics

Focus on preventive measures and novel treatments for high-risk cardiovascular patients.

03 Infectious Disease Research

Studies investigating treatments for Mycobacterium infections and related pulmonary conditions. Evaluation of innovative antibiotic therapies and treatment protocols.

  • Pulmonary Infections
  • Antibiotic Efficacy Studies
  • Treatment Protocol Optimization

Emphasis on comparing different therapeutic approaches for better patient outcomes.

Back to FranceAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.